RhoA as a mediator of clinically relevant androgen action in prostate cancer cells

Lucy J. Schmidt, Kelly Duncan, Neelu Yadav, Kevin M. Regan, Alissa R. Verone, Christine M. Lohse, Elena A. Pop, Kristopher Attwood, Gregory Wilding, James L. Mohler, Thomas J. Sebo, Donald J. Tindall, Hannelore V. Heemers

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

Recently, we have identified serum response factor (SRF) as a mediator of clinically relevant androgen receptor (AR) action in prostate cancer (PCa). Genes that rely on SRF for androgen responsiveness represent a small fraction of androgen-regulated genes, but distinguish benign from malignant prostate, correlate with aggressive disease, and are associated with biochemical recurrence. Thus, understanding the mechanism(s) by which SRF conveys androgen regulation to its target genes may provide novel opportunities to target clinically relevant androgen signaling. Here, we show that the small GTPase ras homolog family memberA(RhoA) mediates androgen-responsiveness of more than half of SRF target genes. Interference with expression of RhoA, activity of the RhoA effector Rho-associated coiled-coil containing protein kinase 1 (ROCK), and actin polymerization necessary for nuclear translocation of the SRF cofactor megakaryocytic acute leukemia (MAL) prevented full androgen regulation of SRF target genes. Androgen treatment induced RhoA activation, increased the nuclear content of MAL, and led toMAL recruitment to the promoter of the SRF target gene FHL2. In clinical specimens RhoA expression was higher in PCa cells than benign prostate cells, and elevated RhoA expression levels were associated with aggressive disease features and decreased disease-free survival after radical prostatectomy. Overexpression of RhoA markedly increased the androgen-responsiveness of select SRF target genes, in a manner that depends on its GTPase activity. The use of isogenic cell lines and a xenograft model that mimics the transition from androgen-stimulated to castration-recurrent PCa indicated that RhoA levels are not altered during disease progression, suggesting that RhoA expression levels in the primary tumor determine disease aggressiveness. Androgen-responsiveness of SRF target genes in castration-recurrent PCa cells continued to rely on AR, RhoA, SRF, and MAL and the presence of intact SRF binding sites. Silencing of RhoA, use of Rho-associated coiled-coil containing protein kinase 1 inhibitors, or an inhibitor of SRF-MAL interaction attenuated (androgen-regulated) cell viability and blunted PCa cell migration. Taken together, these studies demonstrate that the RhoA signaling axis mediates clinically relevant AR action in PCa.

Original languageEnglish (US)
Pages (from-to)716-735
Number of pages20
JournalMolecular Endocrinology
Volume26
Issue number5
DOIs
StatePublished - May 1 2012

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology

Fingerprint Dive into the research topics of 'RhoA as a mediator of clinically relevant androgen action in prostate cancer cells'. Together they form a unique fingerprint.

  • Cite this

    Schmidt, L. J., Duncan, K., Yadav, N., Regan, K. M., Verone, A. R., Lohse, C. M., Pop, E. A., Attwood, K., Wilding, G., Mohler, J. L., Sebo, T. J., Tindall, D. J., & Heemers, H. V. (2012). RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Molecular Endocrinology, 26(5), 716-735. https://doi.org/10.1210/me.2011-1130